Home/Pipeline/CD7-CAR-T program

CD7-CAR-T program

T-cell malignancies

Not specifiedDevelopment

Key Facts

Indication
T-cell malignancies
Phase
Not specified
Status
Development
Company

About PersonGen BioTherapeutics

A Chinese biotech company developing next-generation CAR-T and allogeneic cellular therapies for T-cell cancers and autoimmune diseases.

View full company profile

Therapeutic Areas

Other T-cell malignancies Drugs

DrugCompanyPhase
Non-Gene Editing CARiCell Gene TherapeuticsResearch/Preclinical